Time-dependent thrombolytic resistance is a critical problem in thrombolytic therapy for acute myocardial infarction. Platelets have been regarded as the main source of plasminogen activator inhibitor-1 (PAI-1) found in occlusive plateletrich clots. However, endothelial cells are also known to influence the fibrinolytic capacity of blood vessels, but their ability to actively mediate time-dependent thrombolytic resistance has not been fully established. We will show that, in vitro, tumor necrosis factor-cr-stimulated endothelial cells secrete large amounts of PAL1 over a period of hours, which HE CLINICAL EXPERIENCE from thrombolytic ther-T apy is that early infusion of the thrombolytic agent (within 6 hours) is more successful in establishing reperfusion than later infusions." This time-dependent thrombolytic resistance may have several causes, including factor XIII-induced crosslinking of az-antiplasmin to fibrin,' platelet-induced clot retraction,6 and incorporation of plasminogen activator inhibitor-1 (PAI-1) into the lot.^.^ Whereas the concentration of az-antiplasmin within the clot is mainly influenced by its plasma concentration, PAI-1 can be found in clots in much higher concentrations (up to 200 nmol/L) than in plasma (about 0.4 nmol/L)?.'' The importance of PAI-1 integration into an occlusive clot leading to increased thrombolytic resistance has recently been shown by Levi et all' and Biemond et al.'* These investigators achieved an increase of endogenous thrombolysis and a reduction of thrombus growth by addition of an anti-PAI-1 antibody to a newly formed occlusive clot in a rabbit jugular vein thrombosis model. Therefore, accumulation of PAI-1 happens by active secretion at the site of thrombus growth.
then binds to fibrin and protects the clot from tissue plasminogen activator-induced fibrinolysis. In vivo, endothelial cells covering atherosclerotic plaques are influenced by cytokines synthesized by plaque cells. Therefore, we propose that continuous activation of endothelial cells in atherosclerotic blood vessels, followed by elevated PAI-1 secretion and storage of active PAI-1 in the fibrin matrix, leads to clot stabilization. This scenario makes endothelial calls a major factor in time-dependent thrombolytic resistance. 0 1996 by The American Society of Hematology.
PAL1 and tissue plasminogen activator (t-PA) and thus can act either to enhance or inhibit fibrin~lysis.'~.'~ Under normal conditions, EC are nonthrombogenic. However, it has recently been shown that EC lining atherosclerotic blood vessels contain high amounts of PAI-1.'6,'7 This could be shown by immunohisto~hemistry'~~'~ as well as by mRNA in situ hybridization studies." Even in blood vessels showing no obvious morphologic changes (despite macrophage accumulation or moderate intima thickening), the PAI-1 content of EC is raised." The mechanisms by which the EC of atherosclerotic blood vessels are stimulated are multifaceted, but there is evidence that the macrophages that often directly underlie17." the EC of atherosclerotic plaques enhance the release of PAI-I from EC by direct contact or by factors such as tumor necrosis factor-a (TNF-a) or transforming growth factor$ (TGF-p).2L*22 TNF-a is known to be one of the most potent stimulators of PAI-1 secretion of EC.23," In an extensive ultrastructural study of arteries with atherosclerotic changes of various degrees it could be shown that even highly atherosclerotic plaques are still covered by EC. 25 Therefore, EC covering the walls of atherosclerotic vessels are probably constantly activated by cytokines and become dysfunctional. Endothelial dysfunction, resulting, for instance, in an elevated PAI-1 secretion, is associated with an increase in the risk of acute coronary events. 26 We have previously shown that the supernatant of human umbilical venous EC (HUVEC) in a cell-free model contains sufficient active PAI-1 to delay t-PA-induced lysis of fibrin
In the present experiments, we will explore the hypothesis that the continuous secretion of PAI-1 by EC contributes to the time-dependent thrombolytic resistance both in vitro and during thrombolytic therapy. To test our hypothesis, we established an in vitro model to investigate the formation and subsequent lysis of an occlusive fibrin clot in an artificial blood vessel lined by HUVEC. We will show here a timedependent influence of TNF-a-stimulated HUVEC that increases the thrombolytic resistance of a model fibrin-rich thrombus. Bovine serum albumin, fraction V, was purchased from Sigma (St Louis, MO). Human serum albumin came from the Pharmaceutical Division of Miles Inc (Elkhart, IN).
HUVEC were isolated and cultivated in monolayer according to the method of Jaffe et The umbilical vein of a 20-to 30-cm long piece of nontraumatized umbilical cord was cannulated at both ends and flushed twice with sterile 0.01 m o m HEPESbuffered saline (HBS). The EC were released from the basal lamina membrane using 5 mL of a 0.1 % collagenase solution in HBS (Worthington collagenase I; 161 U/mg; supplied by Cell Systems, Remagen, Germany) at 37°C for 10 minutes. The collagenase solution was flushed out with 20 mL HBS into a sterile 50-mL tube containing 10 mL of Ham'sfiscove's modified Dulbecco's medium (GIBCO 041-01980; GIBCO, Grand Island, NY) with 20% pooled human serum and L-glutamine, penicillin, and streptomycin. After centrifugation for 10 minutes at 200g, the cells were plated in a 25-cmz 0.2% gelatin-coated culture flask (Falcon; supplied by Becton Dickinson Gambil, Heidelberg, Germany) containing 4 mL of Ham'sfiscove's medium with 20% human serum and supplemented with penicillin (100 U/mL), streptomycin (100 pg/mL), and L-glutamine (200 mmoVL). The monolayer cultures were incubated at 37°C in a watersaturated atmosphere of 5% COz in air. Cells were passaged by washing the cultures with HBS and incubating for 15 minutes at 37°C with a 1:l (voVvol) mixture of 0.2% collagenase I in HBS and 0.02% ethylenediaminetetraacetic acid solution (EDTA; tetrasodium salt, dihydrate; Sigma) in HBS containing 0.5% bovine serum albumin (BSA; 35%; Sigma). After centrifuging for 10 minutes at 200g, the cells were resuspended in complete medium and seeded as described below. Cultures were usually passaged using a splitting ratio of 1:3. All cultures were grown in polystyrene culture flasks that had been coated overnight at 4°C with a 0.2% aqueous gelatin solution (research grade; Serva, Heidelberg, Germany). Only cells from the second passage were used for the experiments detailed below.
For the lysis experiments, HUVEC were grown in full medium in fibronectin-coated (5 pg/mL), 6-cm-long glass tubes with an inner diameter of 6 mm and an outer diameter of 8 mm. To achieve a homogenous and circular distribution, the cells were seeded 3 times, using about 2 mL every time with a concentration of 200,000 cells/ mL (3 X 400,000 cells for 1 tube). After each seeding, the tubes were rotated by about 120". Gas exchange was achieved by using silicone tubing at both ends of each glass tube. Filling of the glass tubes with medium or buffer was performed using one-way syringes (5 to 20 mL) with a "Luer-Lock" that fit into connectors at both ends of the silicone tubing (neoLab-Verbinder LUER-L weiblJ4.0-5.0 No. 2-1 889; Heidelburg, Germany). For experiments, cultured HUVEC averaged 85% confluency (range, 75% to 98%). HUVECcoated glass tubes were stimulated with 1,000 U/mL TNF-a (2 nmoV L) in medium with 0.5% HSA for 4 hours before being used in the experiments.
PAI-I antigen concentration was determined by an ELISA kit purchased from American Diagnostica, Inc (Product No. 822/1S). PAI-I present in the sample was read at 490 nm by a Microsoft Vmax Microtiter EC culture.
PAl-1 enzyme-linked immunosorbent assay (ELISA).
Plate Reader (Molecular Devices, Menlo Park, CA). The results were analyzed using the accompanying SOlTmax software package. The standard curve, determined with dilutions of normal plasma, was linear over the range of 0.1 to 50.0 ng/mL PAI-1.
PAI-I activity was determined by using a two-step kit from Biopool [Spectrolyse/pL (VI-]); Biopool AB, Umea, Sweden]. In the first stage, t-PA is added to the plasma sample to react with active PAI-1. Plasmin inhibitors such as a2-antiplasmin are destroyed by acidification. In the second stage, the residual t-PA activity is measured by the conversion of exogenously added plasminogen to plasmin. Plasmin is detected through its hydrolysis of a chromogenic substrate. The amount of color developed and measured at 405 nm is proportional to the amount of t-PA activity and, therefore, inversely proportional to the PAI-1 activity in the sample. The standard curve was linear over the range of 1 to 40
Light-scattering instrumentation. Light-scattering measurements were performed at 37°C with an instrument equipped with a 6-mW He-Ne laser (Model 120; Spectral Physics, Mountain View, CA), a red sensitive R928P photomultiplier tube (Hamamatsu, Middlesex, NJ), and a digital photometer (Pacific Precision Instruments, Concord, CA). The photometer output was collected, digitized, and stored on disk with a Keithley Model DAS-8PGA 8-channel 12-bit analog input board operated in conjunction with the EASYEST LX software package (Keithley Asyst, Rochester, NY) implemented on an AT-compatible microcomputer.
For these experiments, we modified the in vitro model thrombus that we had developed for both light scattering and electron microscopic e~amination.'.~' Laser light scattering was used to monitor the development and lysis of a model thrombus. (perfusion rate, 4 mL/h) with HGA containing plasminogen (100 nmom) and rt-PA (0.5 nmol/L). The clot aging period of 2 to 4 hours was designed to match the interval that typically elapses between the onset of symptoms of a myocardial infarction and the initiation of thrombolytic the rap^.^ This occlusive thrombus model builds on earlier gel permeation experiments that showed that fibrin clots formed within cylindrical glass tubes maintain their structural integrity during slow perfusion with buffered salt sol~tions.~@'~ Furthermore, water comprises 80% of the volume of fibrin gels formed under physiologic conditions of pH and ionic ~trength,'~ and the flow of liquids through these gels conforms to well-established physical-chemical principles."." Rheologic considerations indicate that clinical thrombolysis is often limited by the delivery of rt-PA through an occluded vessel and that the rate of that delivery is limited by pressure-driven permeati~n.'~.~' Both theory" and e~periment-'~ indicate that plasma can perfuse through an occluded artery at a permeation velocity of 0.6 to 1.6 mm/min. Because our occlusive thrombus model uses permeation velocities in the range 0.6 to 1.8 mm/min (10-to 20-minute perfusion times), it is likely that our system provides a reasonable representation of the time required to permeate a thrombus with plasminogen activator and a fresh supply of plasminogen. Therefore, perfusion provides a convenient and reproducible method for delivering components of the fibrinolytic system to the interstices of a preformed fibrin ~l o t . 9~,~~.~~.~~ Our experimental approach is unique in that we have combined laser light scattering measurement~''~'.~ with gel permeation technol-
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Model thrombus system.
For personal use only. Time (min) ogy to develop a noninvasive method of monitoring the growth, aging, and lysis of model thrombi assembled from purified proteins in the presence of cultured EC.
As shown schematically in Fig 1 (inset) , each experiment consisted of four distinct stages: (1) thrombus growth, (2) aging, (3) perfusion, and (4) lysis.
For immunoelectron microscopy, HUVEC were grown in fibronectin-coated (5 pg/mL Fn in phosphate-buffered saline [PBS] for 24 hours) polypropylene tubing having the same dimensions as the glass tubes used for light scattering. Polypropylene tubes were used in EM experiments to facilitate sectioning of the sample after embedding. HUVEC were stimulated for 4 hours in Ham'sflscove's medium + 0.5% HSA with 1,OOO U/ mL TNF-a. After stimulation of the cells, fibrinogen (3 pmoVL), plasminogen (100 nmoVL), and HGA-buffer were added to the tube. Clot formation was initiated by addition of thrombin (to 0.2 U/mL). The cells were then incubated in a 37°C water-saturated incubator with 5% C02. After 2 hours, the clot was perfused once with GH buffer to wash away any loosely bound molecules (perfusion rate, a 4 mL/h). This step was followed by perfusion of the clot with 1% glutaraldehyde in Gey's buffer. After one wash with Gey's buffer containing 0.1% glycine, two washings with Gey's buffer + 1% BSA followed. To reduce background staining, we used 1 vol of a blocking solution containing 5% BSA and 5% nonimmune goat serum. After two additional washings with Gey's buffer + 1% BSA, we did the first incubation by perfusing the clot with 2 vol of the first antibody against human PAL1 (American Diagnostica No. 3780) at 2 pg/mL. After three washings with Gey's + 1% BSA, we incubated with a secondary antibody directed against mouse IgG conjugated
Electron microscopy (EM).
to 30-nm diameter gold particles (Amersham Auroprobe EM GAM IgG G30 RPN426). An unrelated antibody (Amersham Auroprobe EM GAR G15 "422) conjugated to 15-nm gold was included in the incubation to control for nonspecific binding. Antibodies were diluted 1:50 in buffer. The incubation with the second antibody was followed with three additional washings with Gey's + 1% BSA.
After a postfixation with 2 vol 1% glutaraldehyde in Gey's buffer and another wash with Gey's buffer, dehydration was started with 25% ethanol. En-bloc staining with aqueous uranylacetate (1 vol) was followed by another washing step with 25% ethanol. This was followed by perfusion of the clot with 50%. 85%, 95%, and 3X 100% ethanol. Next, 1.5 vol LR White was first perfused in a 1:l mix with 100% ethanol, followed by 2 vol LR White 100%. The embedded clot was polymerized at 60°C in a vacuum oven overnight. Thick sections (1 to 3 pm) were cut from the samples and examined with a Philips CM 30 intermediate voltage electron microscope (IVEM; Philips Electronic Instruments, Mawah, NY). The greater penetrating power of this microscope allowed three-dimensional determination of the distribution of immunogold probe in the samples.
To quantify the distribution of PAI-1, three immunolabeled clots were extensively analyzed. Each clot was thin-sectioned in arbitrary regions along the periphery of the tube and in more centrally located regions. Ten fields from each of these sections were examined. For each clot, this represented 30 pmz of area from each region. The number of specific (30 nm) gold particles was counted and indexed to the length of fibers found in the region to control for variation in fiber density. Nonspecific (15-nm gold) labeling was less than 4% of the total.
Scanning electron microscopy (SEM) was performed to determine 
RESULTS

SEM of the cells in tubes.
Routine light microscopic examination of the cells cultured in glass tubes (for laser light scattering) and plastic tubes (for intermediate voltage electron microscopy) showed no obvious differences between the two culture methods. SEM of selected tubes was used to further assess the characteristics of cells grown on fibronectin-coated glass and fibronectin-coated plastic. SEM analysis confirmed that the appearance of cells grown on these two substrates was not noticeably different and that the degree of confluency was equivalent. Cells averaged 85% confluency (range, 75% and 98%) under both conditions. TNF-a has been reported to produce a variety of effects in EC, from simple disruption of cell-cell contacts4' and growth inhibition'' to cell necrosis4' depending on the concentration and environment." At the concentration we used (1,000 U/mL), most studies have not found TNF-a to be Stimulation of cells with TNF-a under the conditions we used also did not noticeably alter the general appearance or degree of confluency. The stimulated cells looked healthy and there were no signs of damage or necrosis (Fig 2) . Quantitative comparison of two TNF-a-treated and two untreated tubes confirmed that there were no significant differences ( P < .OS) in confluency, size, or shape between cultures treated with TNF-a and those not treated. The degree of confluency was 98% in both cases. Unstimulated HUVEC had an average surface area coverage of 3.68 2 0. I O pm', whereas TNF-a-treated HUVEC covered an average of 3.59 ? 0.1 1 pm2 per cell. The widthnength ratio for unstimulated HUVEC was 0.63 2 0.05 and for stimulated HUVEC the ratio was 0.61 ? 0.05.
To show the influence of EC on the assembly, aging, and lysis of a fibrin-rich thrombus, we compared lysis times of clots either made in the presence or absence of HUVEC. The experiments with aged clots and t-PA-induced lysis were performed as described in Materials and Methods. As shown by the representative light scattering kinetic traces in Fig I , all cases showed a steep increase in scattering intensity that began about 2 to 3 minutes after the addition of thrombin (in both the presence and absence of cells), indicating fiber growth. After the first I O minutes of steep increase, the fibrin-containing medium reached a slow-growing stage, reaching 90% maximum by 20 to 30 minutes. A further 10% increase in scattering intensity was observed over the next 1.5 hours. The start of the perfusion was accompanied by an approximate 10% decrease in scattering intensity; however, once the flow was stopped, the intensity promptly retumed to values similar to those before perfusion.
With no cells present, the scattering intensity started to decline soon after completing the fibrinolytic perfusion. By 1 hour, the clot was totally lysed and the signal had retumed to baseline values (line A . Fig I) . Because it is difficult to determine the time point of total lysis, we compared the lysis half-time (LHT), defined by the time required for the scattering intensity to decrease to half maximum. 
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7 minutes determined in 3 experiments). With nonstimulated HUVEC present, lysis also occurred rapidly, with an LHT of 38 minutes (mean, 38 ? 3 minutes; determined in 4 experiments). In contrast, clot lysis in the presence of TNF-astimulated HUVEC exhibited a clearly prolonged LHT of 93 minutes (mean, 65 2 20 minutes; determined in 5 experiments). We note that the presence of TNF-a-stimulated EC in a 2-hour aged fibrin clot induced a lysis delay of 133% i 66% in comparison to nonstimulated cells. Length of lysis delay depends on duration of cell presence and can be reversed using a PAI-I-resistant plasminogen activator. In the clinical setting, continued clot aging produces enhanced resistance to lysis.'-4 To determine if HU-VEC could mediate a similar enhancement, we compared lysis delay in clots aged for 2 and 4 hours. Figure 3 shows 4 representative light scattering kinetic traces of lysis experiments with clots aged for 2 and 4 hours in the presence of TNF-a-stimulated HUVEC. Curves B and D show those experiments in which lysis was induced by rt-PA, whereas traces A and C are those perfused with the PAI-I -resistant R298E,R299E t-PA. R298E,R299E t-PA is a genetically engineered variant (generously provided by Genentech, Inc) that is nearly resistant to inactivation by PAI-1 because of the arginine-to-glutamic acid substitutions in a region of the t-PA molecule that is directly involved in serpin bindTrace B shows a clearly prolonged rt-PA-mediated lysis (LHT of 68 minutes) after a period of 2 hours, whereas trace D has an even greater prolongation (LHT of 120 minutes) after an incubation time of 4 hours in the presence of TNFa-stimulated HUVEC. The mean LHT value for the 4-hour aging experiments was 117 -t 5 minutes as determined by two experiments. Comparing the effects of the 2-to 4-hour aging experiments, there was an additional 1 &fold delay in clot lysis caused by the additional 2 hours of incubation (Fig clots with nonstimulated EC contained 100 t 30 ng PAI-1 antigen, whereas 200 2 60 ng/mL PAI-1 antigen was recovered when TNF-stimulated EC were present; after 4 hours, these lysates contained 330 t 90 ng/mL PAI-1. Linear regression showed that the resultant LHT were positively correlated with PAI-I antigen secretion in that a threefold increase in PAI-1 antigen corresponded to a 2.3-fold increase in LHT (r = 3).
Using the PAT-I -resistant R298E,R299E t-PA to achieve lysis of clots aged 2 hours (trace A) and 4 hours (trace C), rapid lysis resulted yielding LHT of 24 and 22 minutes, respectively. As summarized in Fig 4, the thrombo-resistant effects of TNF-a -stimulated EC were completely reversed by the genetically engineered PAI-1 -resistant variant R298E,R299E t-PA?5-47 This accelerated lysis occurred even though substantial quantities of PAI-1 antigen were recovered in the lysed clots after treatment with R298E,R299E t- The correlation between PAI-1 Ag concentration and LHT as well as the neutrdizing effect of the PAI-1-resistant R298E,R299E t-PA strongly indicated EC-secreted PAI-1 to be the agent responsible for time-dependent thrombolytic resistance.
Time course of EC secretion of PAI-1: antigen and activity. To determine the time-dependent secretion of PAL1
by TNF-a-stimulated HUVEC within the glass tubes, an experimental arrangement similar to that used for the light scattering experiments was developed. The cells were first stimulated with 1 ,OOO U/mL TNF-a over a period of 4 hours in medium containing 0.5% HSA. After this prestimulation, the medium was changed and the cells were incubated in HGA buffer containing TNF-a. After 30 minutes, 120 minutes, 240 minutes, and 20 hours, aliquots of supematant were taken and PAI-1 antigen and activity were determined. There was an increase in PAI-1 antigen concentration over this interval, reaching a limiting value of 300 5 120 ng/mL PAI-1 antigen after 20 hours. Interestingly, the PAI-1 activity was similar between 2 and 20 hours at 15 5 1 U/mL, so that the relative PAI-1 activity (PAI-1 activityPA1-1 antigen) was highest in the beginning of the experiment. These data indicate that -20% of the PAL1 secreted by TNFstimulated EC during the initial 2-hour period was active; by 20 hours, only -5% of the PAI-1 retained its antifibrinolytic activity.
Incorporation of EC secreted PAI-I into the Jibrin network. Additional experiments were performed to determine the extent to which PAI-1 secreted from HUVEC was bound to fibrin. A clot in a glass tube covered with TNFa-stimulated HUVEC was formed and incubated for 2 hours. The clot was then perfused with HGA buffer at a flow rate of 4 mLh; 10 perfusate samples were obtained in steps of 1 clot volume (0.5 mL each). After this exhaustive perfusion, we induced lysis by perfusion with 1.2 vol of 2 nmol/ L t-PA + 0.1 p m o K plasminogen in GH buffer and took the lysate as another sample. As shown in Fig 5, maximum PAI-1 concentrations of 210 ng/mL and 220 ng/mL were found in the second and third samples (ie, 2 to 3 clot volumes). In the following samples, we found a continuous decrease of PAI-1 concentration. In the lysate, 230 ng/mL PAI-1 was found that had not been washed out during the perfusions and, therefore, most probably had been tightly bound to fibrin. This bound fraction constituted 20% of the total PAI-1 antigen secreted by the stimulated HUVEC. In contrast to the elution pattem for HUVEC-secreted PAI-1, perfusion of a cell-free, control clot resulted in the prompt elution of BSA that was added (to 1.5 mg/mL) before gelation. Continuous monitoring of the absorbance at 280 nm showed a sharp, nearly symmetric peak centered at 1 clot volume of eluate; 90% of this UV absorbing material was eluted in the first 2.5 clot volumes. This observation that albumin eluted from a fibrin clot much more readily than PAI-1 provides additional support for the postulate that EC-secreted PAI-1 binds specifically to fib1in.2~ To further verify the incorporation of PAI-1 into the clot and to determine to what extent the PAL1 produced by the HU-VEC had diffused throughout the fibrin clot, we performed immunoelectron microscopic experiments. HUVEC were seeded in segments of transfer pipettes that had been fibronectin-coated in the same way as the glass tubes. A clot was formed and aged as described for the light scattering experiments. IVEM analysis of the clot showed extensive binding of PAL1 to fibrin fibers throughout the clot. Figure  6 shows the immunolocalization of endothelium-derived PAI-1 in regions of the clot proximal to the cells. After the 2-hour aging period, PAI-1 was bound specifically to fibrin fibers, whereas the endothelial surface itself was devoid of PAI-1 antigen. PAI-1 was also found in the center of the clot, distal to the endothelium. However, quantitation of gold distribution showed a greater density of PAI-1 binding in the peripheral regions (near EC) than in the central ones (away from EC). For three separate experiments, the average count of gold particles near the edge adjacent to HUVEC was 1.1 t-0.1 particledpm fibrin, whereas the average count from the samples from the middle of the clot was 0.38 2 0.05 particledpm fibrin. Thus, HUVEC-secreted PAL1 penetrated throughout the clot but was 2.8 times more concentrated near H W E C than in the center of the clot (Fig 7) .
A calculation of the PAI-1 distribution expected within the fibrin clot was made using the mathematical solution to the diffusion equation that applies when an initially thin band of concentrated macromolecules is allowed to spread,
Immunolocalization of PAI-I within the thrombus.
For
Stereo pair of immunoelectron microscopic staining for PAI-1 within a 2-hour aged fibrin clot made in the presence of TNFastimulated HUVEC. Dense fibrin fibers can be seen overlaying an EC in the background. Endogenous PAL1 secreted from HUVEC is detected with PAL1 antibody conjugated to 30-nm gold particles, whereas an unrelated antibody, which should not bind, was conjugated with 15-nm gold colloids. The micrograph shows that large quantities of PAI-1 are bound specifically to fibrin after the 2-hour aging period. Nonspecific 115-nm gold particle) binding was less than 4% of the total binding. (Original magnification x 21,000.)
driven by Brownian
The translational diffusion coefficient for PAI-I was calculated by treating the 47-kD macromolecule as a hydrated ellipsoid 4 nm wide X 7 nm long, dimensions derived from crystallographic data.49 Correction was made for the increased diffusion expected at 37°C. as well as for the moderately restrictive effects of a fibrin gel (which is 80% water) on macromolecular motion.".5" Figure 7 includes an overlay of this calculated distribution of PAI-I within the clot and the quantitative data from the immunoelectron microscopic staining of the clot. The agreement is quite satisfactory, especially considering that, as a first-order approximation, we have assumed that HU-VEC secretion initially yields a concentrated solution of Overlay of the calculated distribution pattern of EC-secreted PAL1 from the walls of the glass blood vessel through the fibrin network over a period of 2 hours at 37°C based solely on diffusion (solid line) and the actual distribution pattern of PAL1 within the fibrin clot determined by quantitation of electron microscopic immunogold staining (bars). The agreement between theory and experiment implies that PAL1 distribution is mainly influenced by diffusion.
PAI-1 near the walls of the glass blood vessel. Continued secretion of PAI-1 by the stimulated HUVEC would probably increase the quantity of inhibitor present in the clot, whereas restricted diffusion through the gel would act to limit its spread. On one hand, other investigators have experimentally determined that a macromolecule of similar size to PAI-I, ie, BSA, diffuses through dilute fibrin gels at a rate ~9 7 % of that in water?" On the other hand, avid binding of PAI-I to the fibrin strands should result in a sequestration of active PAI-I on the surface of individual fiber^.^.^.^'.^^ The experimentally determined distribution of PAL 1 probably is influenced by these competing processes of free diffusion through the clot and adherence to the fibrin strands. The resultant enrichment of fibrin in EC-secreted PAI-I is thus a major mechanism of time-dependent thrombolytic resistance.
DISCUSSION
Approximately 20% of infarcted arteries fail to open with thrombolytic regimen^.^"'^ Thrombolytic therapy applied during the first 6 hours after the onset of chest pain is more successful than later therapies.I4 The reasons for this timedependent thrombolytic resistance are still under discussion. Growing clot density by factor XIII-mediated crosslinking of fibrin: platelet-induced clot retraction," tight adhesion of fibrin to cell surface integrin receptors,"".'' and incorporation of inhibitors of plasmin and plasminogen activators into the lot^.'.'".^^ have all been postulated to cause thrombolytic resistance. PAL1 has been found in much higher concentrations in platelet-rich white thrombi (20 to 200 nmol/L) than in platelet-poor red thrombi.'.'' Considerable experimental data indicate that PAI-1 released from platelets definitely delays clot lysis,7.' and it was recently shown that the use of a PAI-I inhibiting antibody in a rabbit animal model results in increased endogenous thrombolysis and reduced thrombus growth.".'* From these data, platelets have been regarded to be the main contributors for an elevated thrombolytic resistance?*13 However, given the rapid release of platelet PAI-1 and its low specific activity, we suggest that EC-derived PAI-1 may play a critical role in the time-dependent increase in thrombolytic resistance. Recent data showing increased expression of PAL1 mRNA in EC lining fresh thromboemboli of pulmonary blood vessels indicate an active role of EC in the stabilization of thrombi.56 Immunohistochemical and in situ hybridization studies of coronary arteries reveal an increase of PAL1 antigen and mRNA mainly in atherosclerotic lesions." Endothelial PAI-1 expression visualized as characteristic of activated luminal endothelium was shown to be more pronounced in arteries with mild thickening of the intima or fatty streaks than on complicated lesion^.'^ Just in these areas, a subintimal accumulation of macrophages can be found. Macrophages are known to stimulate the PAI-1 secretion in part by direct cell-cell interaction or by release of soluble factors such as TNF-a or TGF-/??1*22 From these data we conclude that EC lining atherosclerotic blood vessels seem to be continuously activated and, especially with a freshly built clot or overlaid embolus, seem to secrete significantly higher amounts of PAI-1 than nonactivated cells. The lysis experiments with our in vitro model mirror these in vivo findings and show that nonactivated HUVEC have only a small effect on lysis while activated cells clearly delay lysis.
The time course of PAL1 released by EC and the cell effect on thrombolytic resistance shown here strongly imply a major role of EC in confemng time-dependent thrombolytic resistance. EC contain and secrete active PAI-1, which normally is cleared or inactivated within With fibrin strands of a freshly built clot near the EC surface, active PAI-1 is bound to the fibrin strands, thus protected against inactivation and still able to react with its main antagonist t-PA.52,58 This integration of (active) PAL1 into the thrombus could be shown by the high concentrations of PAI-1 that were still present after exhaustive washing of the fibrin clot formed in the presence of TNF-a-stimulated EC.
Applying the principles of quantitative affinity chromatogr a p h~~~ to this PAL1 elution data, we obtained an estimate of the dissociation constant for the PAI-1:fibrin complex of -1 pmoYL. This value agrees reasonably well with the observation that both activated and latent PAI-1 bind to fibrin primarily through a large number of low-affinity sites, characterized by dissociation constants of 3.8 pmol/L and 1.4 pmol/L, respectively.' Furthermore, data presented here indicate that -20% of the EC-secreted PAL1 was active 2 hours after stimulation by TNF-a and that -20% of the EC-secreted PAI-1 remained bound to the fibrin clot after extensive washing. These observations suggest that the active PAI-1 conformers secreted by TNF-stimulated EC may have been selectively retained on the fibrin matrix. Immunoelectron microscopic localization of PAI-1 confirmed this finding, and the kinetic experiments shown here prove that the PAI-1 incorporated into the clot is active.
Using the PAI-1 -resistant R298E,R299E t-PA, we have shown that the delay in lysis caused by EC in our system is mainly an effect of PAI-1. The ixnmunoelectron microscopy showed a distribution pattern of PAI-1 within the clot that mainly depends on diffusion effects. Thus, we observed the highest concentrations of PAL1 near the EC. Further into the center of the clot the PAI-1 staining became less intense. Despite this, we could show that PAI-1 diffuses over at least 3 mm within 2 hours. This observation is consistent with the calculated translational diffusion coefficient of PAL 1 and with the additional observation that macromolecules of molecular mass up to 68,000 daltons can diffuse relatively freely throughout a fibrin clot.% However, the actual distribution of PAL1 within an aging thrombus will be influenced by ongoing cellular secretion of the inhibitor, as well as its binding to the fibrin network. From these data we can speculate that secretory products of EC can influence an occlusive clot in a coronary artery of similar size within a matter of hours. In smaller blood vessels, the EC-mediated clot stabilizing effect may even be larger.
With the experimental data presented here we could show that, by way of diffusion alone, EC-derived PAL1 can infiltrate an occlusive clot in a blood vessel comparable in size to a human coronary artery. The presence of activated HUVEC mimics the time-dependent thromboresistance seen in clinical trials for myocardial infarction.I4 Therefore, clot stabilizing dysfunctional EC have to be regarded as an important factor for thrombolytic therapy failure. This knowledge implies a new concept for thrombolytic therapy, ie, treatment of dysfunctional EC could help to reduce the risk of thrombosis in stenotic blood vessels and, once an infarction happens, thrombolytic therapy could be more effective because of the reduced time-dependent thrombolytic resistance.
